Posted On: 11/18/2014 11:04:13 AM
Post# of 30066
Several things, such as:
Final data on LP002 with extension
CLIA data
RUO launch
RUO deals announced
Eltoprazine FDA response, maybe with a surprise that is eligible to start a Phase 3 trial - that would be massive, because BP would be all over this...
Eltoprazine IND submission, maybe approval before end of year
MANF IND approval for Retinitis Pigmentosa - did I also hear European submission on the call?
MANF IND submission for CRVO
These are all things that have a very high likelihood of occurring.
Btw-they are very keen on Uplisting out of the OTC nightmare. Even if they have to do a larger than expected RS, which I don't think they will, the dividend that GC mentioned will more than make up for it. Then shareholders will hold shares tightly because they know Lympro will be sold and make us all a large chunk of Washington's...
Final data on LP002 with extension
CLIA data
RUO launch
RUO deals announced
Eltoprazine FDA response, maybe with a surprise that is eligible to start a Phase 3 trial - that would be massive, because BP would be all over this...
Eltoprazine IND submission, maybe approval before end of year
MANF IND approval for Retinitis Pigmentosa - did I also hear European submission on the call?
MANF IND submission for CRVO
These are all things that have a very high likelihood of occurring.
Btw-they are very keen on Uplisting out of the OTC nightmare. Even if they have to do a larger than expected RS, which I don't think they will, the dividend that GC mentioned will more than make up for it. Then shareholders will hold shares tightly because they know Lympro will be sold and make us all a large chunk of Washington's...
(0)
(0)
